Carbapenemase producers are a nightmare for clinicians. Not only are they resistant to carbapenems, a last resort β-lactam antibiotic, they are notorious for developing multidrug and pandrug resistances resulting in limited to no treatment options. In this episode of Communicable, hosts Angela Huttner and Thomas Tängdén sit down with Dr. David Paterson (National University of Singapore) and Dr. Souha Kanj (American University of Beirut Medical Center, Lebanon), two ID physicians from regions where carbapenem-resistant Enterobacteriaceae or CRE, and carbapenem-resistant Acinetobacter are widespread. The episode begins with the history and emergence of CRE and reviews current epidemiology, diagnosis (including the Ambler classification of β-lactamases) and treatment options. Lessons and insights from personal experiences are shared to reflect the current clinical challenges caused by carbapenem-resistant bacteria and the importance of infection prevention and control measures to mitigate further spread.
This episode was edited by Kathryn Hostettler and peer-reviewed by Dr. Filippo Medioli of Policlinico di Modena, Italy. For more related content on the WHO Priority Pathogens List and new antibiotics in the pipeline, check out our previous episodes, Communicable E3 and E10 (see Literature).
Literature
Wagenlehner FM, et al. Cefepime-Taniborbactam in Complicated Urinary Tract Infection.
N Engl J Med 2024 Feb. doi:
10.1056/NEJMoa2304748
Cohn J, et al. Accelerating antibiotic access and stewardship: a new model to safeguard public health.
Lancet Infect Dis 2024 Sep. doi:
10.1016/S1473-3099(24)00070-7
Paterson DL. Antibacterial agents active against Gram Negative Bacilli in phase I, II, or III clinical trials.
Expert Opin Investig Drugs 2024 Apr. doi:
10.1080/13543784.2024.2326028